EPHA2 and breast carcinoma: Amongst the prioritized genes, 9 are rarely altered (in <1% of the samples, at most 10 alterations in the breast cancer dataset, i.e. BCL2L1, CDC42, DDX5, AKT1, VAV2, EPHA2, CRK, UFD1L, NGFR and APC), indicating our method is able to also prioritize genes with few genomic alterations.